NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Kyndryl Holdings, Inc. (NYSE: KD) between August 7, 2024 and February 9, 2026, both dates inclusive (the “Class Period”), of the important April 13, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Kyndryl securities during the Class Period you may be entitled to compensation without payment of any out of pocket ...

HAUPPAUGE, N.Y., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) today announced that, subject to shareholder approval, it will change its name to “Dime Commercial Bancshares, Inc.”. The Bank’s name will change to “Dime Commercial Bank”. These changes will be effective soon after the Annual Shareholder Meeting (May 28, 2026), where there will be a vote to approve the Company’s name change. The Company is also ...

$12.3 Million YTD in New Contract AwardsCALGARY, Alberta, Feb. 23, 2026 (GLOBE NEWSWIRE) -- CEMATRIX Corporation (TSX: CEMX) (OTCQB: CTXXF) ("CEMATRIX" or the "Company"), a specialty construction contractor that produces cellular concrete solutions on site and is a leading manufacturer and supplier of cellular concrete in North America announces that it has won $5.2 million in new contract awards. New Contract Award Details: The awards are in the form of contracts and contracts in process. Some of this work ...

CALGARY, Alberta, Feb. 23, 2026 (GLOBE NEWSWIRE) -- CEMATRIX Corporation (TSX: CEMX) (OTCQB: CTXXF) ("CEMATRIX" or the "Company"), a specialty construction contractor that produces cellular concrete solutions on site and is a leading manufacturer and supplier of cellular concrete in North America announces that it has won $5.2 million in new contract awards. New Contract Award Details: The awards are in the form of contracts and contracts in process. Some of this work related to these awards should be compl ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- AMC Networks Inc. (the “Company” or “AMC Networks”) (Nasdaq: AMCX) today announced the commencement of an exchange offer (the “Exchange Offer”) to Eligible Holders (as defined below) to exchange any and all of its outstanding 10.25% Senior Secured Notes due 2029 (the “Old Notes”) for its newly-issued 10.50% Senior Secured Notes due 2032 (the “New Notes”), on the terms and subject to the conditions set forth in a Confidential Offering Memorandum and Consent Solicit ...

VANCOUVER, British Columbia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company") is pleased to announce that, further to its news release dated February 17, 2026, the Company has closed the first-tranche of a non-brokered private placement of unsecured convertible debentures of the Company (each, a “Debenture”) for a principal amount of $300,000 (the “Offering”). The Debentures will bear interest from their issue date at ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- AMC Networks Inc. (“AMC Networks” or the “Company”) (Nasdaq: AMCX) announced today the receipt of Requisite Consents (as defined below) from holders of its existing 10.50% Senior Secured Notes due 2032 (the “Notes”) and the effectiveness of amendments to the indenture governing the Notes to (1) amend the covenant that limits restricted payments in order to permit buybacks, purchases, redemptions, retirements or other acquisitions of AMC Networks Inc.’s equity inte ...

Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ETWAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will host ...

WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will host a conference call and webcast tomorrow, Tuesday, February 24, 2026, at 8:00am ET to disc ...

Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health and future expenses during its IPO, leading to significant stock price declines after the IPO [1][3][4]. Company Overview - Navan, Inc. operates an AI-powered software platform aimed at simplifying travel and expense management for users, customers, and suppliers [2]. IPO Details - Navan conducted its IPO on October 31, 2025, issuing nearly 37 million shares at an offering price of $25.00 per share [2]. Allegations of Misleading Information - The lawsuit claims that the IPO offering documents were materially false or misleading, particularly regarding a 39% increase in sales and marketing expenses shortly after the IPO, which was necessary to sustain revenue growth [3]. Financial Impact - On December 15, 2025, Navan reported a significant increase in sales and marketing expenses to nearly $95 million, up from $68.5 million in the previous quarter, which contributed to a nearly 12% drop in stock price following the announcement [4]. - By the time the lawsuit commenced, Navan's stock price had fallen to as low as $9.20 per share, representing a decline of nearly 63% from the IPO price [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Navan common stock during the IPO to seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, marking its fourth 1 ranking in the past five years [7].